LIB Therapeutics takes its $199-a-month PCSK9 strategy into an autoinjector for 2027
FDA has approved a single-use LEROCHOL autoinjector and revised the drug’s labeling, with LIB Therapeutics planning US availability by January 2027.
Pharma & Biotech
Pharma & Biotech
Why LIB Therapeutics’ lerodalcibep data matter for next-generation cholesterol care
Monthly PCSK9 therapy is getting crowded. LIB Therapeutics’ LEROCHOL data raise a sharper question on adherence, access and durability.